Decision of the EEA Joint Committee No 65/2024 of 15 March 2024 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2024/1625]
Date: 2024-03-15
Institutions: EEA Joint Committee
Subjects: EU Member State, European Economic Area, chemical product, distillation, fats, market approval, plant health control, plant health product, revision of an agreement




L_202401625EN.000101.fmx.xml












Official Journal of the European Union


EN
L series













2024/1625


4.7.2024







            DECISION OF THE EEA JOINT COMMITTEE No 65/2024
of 15 March 2024
         
amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2024/1625]


THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,

Whereas:







(1)


Commission Implementing Regulation (EU) 2023/1755 of 11 September 2023 renewing the approval of the low-risk active substance fat distillation residues in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011 (1), as corrected by OJ L, 2023/90211, 22.12.2023, is to be incorporated into the EEA Agreement.












(2)


Commission Implementing Regulation (EU) 2023/1756 of 11 September 2023 renewing the approval of the low-risk active substance Cydia pomonella granulovirus (CpGV) in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) No 540/2011 (2) is to be incorporated into the EEA Agreement.












(3)


Commission Implementing Regulation (EU) 2023/1757 of 11 September 2023 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances bensulfuron, chlormequat, chlorotoluron, clomazone, daminozide, deltamethrin, eugenol, fludioxonil, flufenacet, flumetralin, fosthiazate, geraniol, MCPA, MCPB, propaquizafop, prosulfocarb, quizalofop-P-ethyl, quizalofop-P-tefuryl, sodium 5-nitroguaiacolate, sodium o-nitrophenolate, sodium p-nitrophenolate, sulfuryl fluoride, tebufenpyrad, thymol, and tritosulfuron (3) is to be incorporated into the EEA Agreement.












(4)


Commission Implementing Regulation (EU) 2023/1784 of 15 September 2023 amending Implementing Regulation (EU) No 686/2012 as regards the allocation to Member States, for the purposes of the renewal procedure, of the evaluation of etoxazole whose approval expires on 31 January 2028 (4) is to be incorporated into the EEA Agreement.












(5)


Annex II to the EEA Agreement should therefore be amended accordingly,





HAS ADOPTED THIS DECISION:



Article 1
Chapter XV of Annex II to the EEA Agreement shall be amended as follows:






1.


The following indents are added in point 13a (Commission Implementing Regulation (EU) No 540/2011):






‘—



32023 R 1755: Commission Implementing Regulation (EU) 2023/1755 of 11 September 2023 (OJ L 224, 12.9.2023, p. 18), as corrected by OJ L, 2023/90211, 22.12.2023,










—



32023 R 1756: Commission Implementing Regulation (EU) 2023/1756 of 11 September 2023 (OJ L 224, 12.9.2023, p. 23),










—



32023 R 1757: Commission Implementing Regulation (EU) 2023/1757 of 11 September 2023 (OJ L 224, 12.9.2023, p. 28).’














2.


The following indent is added in point 13zzze (Commission Implementing Regulation (EU) No 686/2012):






‘—



32023 R 1784: Commission Implementing Regulation (EU) 2023/1784 of 15 September 2023 (OJ L 229, 18.9.2023, p. 89).’














3.


The following points are inserted after point 13zzzzzzzzzzzzzx (Commission Implementing Regulation (EU) 2023/741):






‘13zzzzzzzzzzzzzy.



32023 R 1755: Commission Implementing Regulation (EU) 2023/1755 of 11 September 2023 renewing the approval of the low-risk active substance fat distillation residues in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011 (OJ L 224, 12.9.2023, p. 18), as corrected by OJ L, 2023/90211, 22.12.2023.










13zzzzzzzzzzzzzz.



32023 R 1756: Commission Implementing Regulation (EU) 2023/1756 of 11 September 2023 renewing the approval of the low-risk active substance Cydia pomonella granulovirus (CpGV) in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) No 540/2011 (OJ L 224, 12.9.2023, p. 23).’










Article 2
The texts of Implementing Regulations (EU) 2023/1755, as corrected by OJ L, 2023/90211, 22.12.2023, (EU) 2023/1756, (EU) 2023/1757 and (EU) 2023/1784 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.


Article 3
This Decision shall enter into force on 16 March 2024, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1).


Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.




Done at Brussels, 15 March 2024.


For the EEA Joint Committee


The President

Nicolas VON LINGEN
            





(1)  
            OJ L 224, 12.9.2023, p. 18.

(2)  
            OJ L 224, 12.9.2023, p. 23.

(3)  
            OJ L 224, 12.9.2023, p. 28.

(4)  
            OJ L 229, 18.9.2023, p. 89.

(*1)  No constitutional requirements indicated.


ELI: http://data.europa.eu/eli/dec/2024/1625/oj
ISSN 1977-0677 (electronic edition)